Saluda Medical Secures $100M Funding to Revolutionize Neuromodulation Therapy

Saluda Medical is thrilled to announce a significant milestone in its journey to transform the field of neuromodulation with the successful completion of a $100 million funding round. This investment will be pivotal in advancing Saluda Medical's mission to provide innovative solutions for patients suffering from debilitating neurological disorders. Known for its pioneering Evoke® System, the world's only ECAP-controlled closed-loop spinal cord stimulation (SCS) system, Saluda is poised to set new benchmarks in chronic pain management. The Evoke System's ability to instantaneously read, record, and adjust stimulation based on nerve responses has proven to deliver superior outcomes compared to traditional open-loop systems, as evidenced by the promising results from the groundbreaking EVOKE study published in respected journals such as The Lancet Neurology and JAMA Neurology. These results not only highlight the system's effectiveness in alleviating pain but also its impact on improving patients' quality of life. With the funding raised, Saluda Medical will enhance its efforts in product development, regulatory compliance, and market expansion. The company has already made strides in the European marketplace where Evoke is CE marked and commercially available, and is excited for its upcoming full commercial release in the U.S. later this year, following FDA approval. The investment represents confidence in Saluda's unique approach to neuromodulation and serves as a testament to its commitment to bringing transformative therapies to patients in need. For more information about Saluda Medical and to stay updated on its initiatives, please visit www.saludamedical.com.